Stockwinners Market Radar for January 26, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:32 EST Cathie Wood's ARK Investment bought 125.7K shares of Teladoc today

20:30 EST Cathie Wood's ARK Investment bought 120.3K shares of Compass Pathways today

18:32 EST Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer's disease - Eisai (ESALY) and Biogen (BIIB) announced that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer's disease with confirmed amyloid pathology, for review following a standard timeline.

18:24 EST Nucor CEO: Our team is firing on all cylinders - In an interview on CNBC's Mad Money, Leon Topalian said the company's acquisition efforts are going very well and position it for further growth. He expects current profit trends to continue in 2023. Nucor's capital allocation strategy allows it to meet the steel demands of today, he noted. He expects the IRA and Chips Act to serve as tailwinds for the company.

18:01 EST Canoo appoints Ken Manget as CFO - Canoo named Ken Manget, CFO. Ramesh Murthy, who served as interim CFO, will continue in his role as Senior VP, Finance and CAO. Manget has many years of financial industry experience on the buy and sell side, including running a multi-billion global equity investment strategy at Ontario Teachers' Pension Plan, and having originated and closed several billion of equity, debt and structured finance transactions while at BMO Capital Markets.

17:27 EST Northern Oil and Gas to replace South Jersey Industries in S&P 600 at open 2/2 - Infrastructure Investments Fund is acquiring South Jersey Industries in a deal expected to be completed soon pending final conditions.

17:23 EST Ford expands complimentary pick-up & delivery mobile service nationwide - Ford said in part, earlier, in statement on its web site: "Ford customers nationwide now can enjoy complimentary Pickup & Delivery as well as expanded mobile services from participating dealers as part of the company's increased commitment to enhancing the ownership experience... 'This program increases the access customers have to remote service options, so whether you're due for an oil change or need to resolve a recall, it's easier to have your vehicle serviced with less disruption to your life, and the activities and people you care about...' The expanded program provides dealers with additional support to offer the complimentary remote services...'By expanding the remote experiences offerings, we can accelerate our ability to be there for customers whenever and wherever they need us." With Pickup & Delivery, the customer's preferred Ford dealer will come to their home or place of business, pick up their vehicle and return it when the repair has been completed. ..For light repairs and routine maintenance, a Mobile Service van can be dispatched with a trained technician to perform service at an eligible location of the customer's choice..." Reference Link

17:17 EST Bachoco CEO Rodolfo Ramos Arvizu to retire - Industrias Bachoco S.A.B. de C.V. announces the starting of the retirement process of its Chief Executive Officer Mr. Rodolfo Ramos Arvizu. The Company named Mr. Ernesto Salmon Castelo as its new Chief Executive Officer. Mr. Salmon joined the Company in 1991.

17:10 EST Trinseo sees Q4 net loss from continuing operations ($367M)-($362M) - Sees Q4 adjusted EBITDA $4M-$$9M. Net loss includes a pre-tax, non-cash goodwill impairment charge of $297M related to the PMMA business and Aristech Surfaces reporting units. CEO Frank Bozich said, "Our Q4 results reflect a challenging operating environment including a continuation of customer destocking, lower underlying demand, and volume and margin impacts from lower-cost imports into Europe from Asia. As a result, our earnings and cash generation were below our previous expectations. However, due to proactive operating decisions such as idling styrene production throughout Q4, we saw a considerable sequential Adjusted EBITDA improvement of more than $40M. Further improvement in Q1 is expected given seasonally stronger demand, lower energy prices and the realization of our asset restructuring initiatives. Despite the near-term challenges, we remain very optimistic about these businesses. Sales volume has been impacted by weak underlying demand and continued customer destocking. In addition, both volume and margins were pressured as elevated natural gas prices in Europe and low demand in China created an arbitrage window for lower-cost commodity products from Asia to be more heavily imported into Europe and North America. We view both of these as temporary circumstances which we believe will resolve themselves in the coming quarters."

17:05 EST Partner Communications trading resumes

17:03 EST Partner Communications announces delisting from Nasdaq - Partner Communications announced that it intends to voluntarily delist its American Depositary Shares from the NASDAQ Global Select Market and concentrate its share trading on one single exchange, the Tel Aviv Stock Exchange. Following the effectiveness of the delisting from NASDAQ, the Company intends to deregister and terminate its reporting obligations with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The company will maintain the current listing of its shares on TASE, which will become Partner's only official stock exchange listing.

17:01 EST SmartFinancial raises quarterly dividend 14% to 8c per share - SmartFinancial announced that on January 26, 2023, the board of directors of SmartFinancial declared a quarterly cash dividend of 8c per share of SmartFinancial common stock payable on February 27, 2023, to shareholders of record as of the close of business on February 10, 2023. The 8c per share quarterly dividend represents a 14% increase over SmartFinancial's prior quarterly dividend declared in October 2022 of 7c per share.

16:55 EST Charles Schwab raises quarterly dividend by 14% to 25c per share - The dividend is payable February 24, 2023 to stockholders of record as of the close of business on February 10, 2023.

16:39 EST Ellington Financial estimates book value per share of $15.05 as of Dec 31 - Ellington Financial announced its estimated book value per share of common stock of $15.05 as of December 31, 2022. This estimate includes the effect of the previously announced monthly dividend of $0.15 per share of common stock, payable on January 25, 2023 to holders of record on December 30, 2022, with an ex-dividend date of December 29, 2022.

16:35 EST Granite awarded roughly $46M contract by Caltrans - Granite has been awarded an approximately $46M contract by the California Department of Transportation to improve safety and mobility along U.S. Highway 101 in Humboldt County, California. The project will be funded by the Federal Highway Administration and was included in Granite's fourth quarter 2022 CAP. "This project includes several unique construction features to address challenging subsurface conditions and completion will result in safer passage along this stretch of highway," said Granite VP of Regional Operations, Brent Fogg. "The Indianola Interchange project is in direct alignment with our strategic plan for geographic growth and adds to our presence in the Humboldt County market, strengthening our relationship with Caltrans District 1." The project will begin in the Spring of 2023 and is expected to be completed in 2025.

16:32 EST OneSpan to acquire ProvenDB - OneSpan "announced that it has agreed to acquire ProvenDB, an Australia-based startup that delivers secure storage and vaulting for documents based on blockchain technology, to provide an industry-leading trust model for high assurance contracts and documents. ProvenDB will extend the capabilities of OneSpan's Transaction Cloud Platform to both public and private blockchains and serve as a modern technological foundation for high assurance business processes for Web3. ProvenDB has been at the forefront of developing secure storage, leveraging blockchain technology that adds a layer of security to prevent data tampering or alteration of documents. When information is added to ProvenDB, digital signatures are created and posted to an immutable public blockchain. ProvenDB's secure storage and vaulting solutions provide proof of the integrity, ownership and creation date of critical information."

16:31 EST Marqeta names Simon Khalaf as CEO - Marqeta "announced the appointment of Simon Khalaf as its new Chief Executive Officer, effective January 31, 2023. Khalaf will also join Marqeta's Board of Directors. As announced in August, Jason Gardner, Marqeta's founder, Chairman, and current Chief Executive Officer, will become Executive Chairman upon this new appointment. Khalaf joined Marqeta in June of 2022 as Chief Product Officer and has also taken on leadership of the Go-to-Market organization since last August. Alongside Simon's appointment, ex-Google and Ancestry Executive Todd Pollak joins the company as Chief Revenue Officer."

16:28 EST Hasbro falls 4% to $61.21 after below-consensus Q4 pre-announcement

16:25 EST Hasbro COO Eric Nyman steps down - The company states: "In October 2022, the Company announced a goal of delivering $250M-$300M in annualized run-rate cost savings by year-end 2025. In alignment with this program's objectives, the Company is undertaking organizational changes that will result in the elimination of approximately 1,000 positions from its global workforce this year, or approximately 15% of global full-time employees. The changes will include a new organizational model, commercial alignment, and leadership changes that the Company will discuss in more detail on its upcoming earnings conference call. As part of these organizational and commercial changes, Eric Nyman, president and chief operating officer, is departing Hasbro. At this time, the Consumer Products business will report directly to the CEO."

16:24 EST Celularity: 'Substantial' portion of workforce may be impacted by objectives - As part of Celularity's reprioritization efforts, the company has notified a substantial portion of its workforce that their employment may be impacted in order to achieve its strategic objectives. While Celularity is hopeful that there will be no need to substantially reduce its headcount, the notifications were provided in accordance with applicable law and to maintain full transparency with its employees.

16:22 EST Celularity completes strategic review of 2023 initiatives - Celularity announced the results of a strategic review of its 2023 key initiatives. This strategic review included the recently announced territory distribution agreement covering more than 100 countries for Celularity's Halal-Certified products and the exclusive distribution agreement with the Tamer Group in Saudi Arabia. Celularity's review also included pipeline prioritization and targeted expense reductions to align operating priorities in advance of an anticipated biomaterials production ramp-up this year. "Celularity's novel business model leverages a diversified portfolio of therapeutic technologies all derived from a single source material - the post-partum placenta. As the Company that pioneered the use of placental-derived stem, progenitor and immune cells, and as an innovator in placental biomaterial product development, Celularity's business model is to generate commercial revenue from both cellular and regenerative therapeutics, including technologies that combine cellular and regenerative therapeutics. Already this year, we've been presented with a series of unique opportunities, and the environment continues to be extremely favorable," said Robert J. Hariri, M.D., Ph.D. Celularity's CEO, Chairman and Founder. "As we invest to scale production of our commercial biomaterial products to meet expected demand in the United States and the Middle East, we are prioritizing our most promising cell therapy product candidates and programs, and are rebalancing our workforce and identifying targeted expense reductions to support these priorities."

16:18 EST CB Financial Services board increases quarterly dividend 4.2% to 25c - The company's Board of Directors has approved a 4.2% increase in the regular quarterly cash dividend by declaring a 25c quarterly cash dividend per outstanding share of common stock, payable on or about February 28, 2023, to stockholders of record as of the close of business on February 15, 2023.

16:16 EST Sana says FDA okays new new drug IND application for SC291 B-cell study - Sana Biotechnology announced the U.S. Food and Drug Administration FDA has cleared the company's Investigational New Drug IND application to initiate a first-in-human study of SC291 in patients with various B-cell malignancies. SC291 is a CD19-targeted allogeneic CAR T cell therapy developed using Sana's hypoimmune platform. The goal of the hypoimmune platform is to overcome the immunologic rejection of allogeneic cells, which if true for SC291 may result in longer CAR T cell persistence and a higher rate of durable complete responses for patients with B-cell lymphomas or leukemias. The hypoimmune platform includes disruption of major histocompatibility class I and MHC class II expression to hide cells from the adaptive immune system, which includes antibody and T cell responses, as well as overexpression of CD47 to inhibit activation of the innate immune cell system, in particular macrophages and natural killer cells. The company has presented data across multiple preclinical models highlighting the potential of this platform to cloak cells from immune recognition and the potential of SC291 as a therapeutic for patients with B-cell malignancies.

16:12 EST PCB Bancorp announces amendment to stock repurchase plan - PCB Bancorp announced that on January 26, 2023, its Board of Directors approved an amendment to its current repurchase program that was approved and announced on July 28, 2022. The original repurchase program authorized the repurchase of up to 5% of the Company's outstanding common stock as of the date of the board meeting, which represented 747,938 shares, through February 1, 2023. The Repurchase Program Amendment extends the expiration date from February 1, 2023 to February 1, 2024. As of January 26, 2023, the Company repurchased and retired 416,275 shares of its common stock, leaving an aggregate of 331,663 shares in authorized repurchase authority that is the subject of the Repurchase Program Amendment. Under the stock repurchase program, the Company may purchase shares of its common stock through various means such as open market transactions, including block purchases, and privately negotiated transactions. The number of shares repurchased and the timing, manner, price and amount of any repurchases will be determined at the Company's discretion. Factors include, but are not limited to, stock price, trading volume and general market conditions, along with the Company's general business conditions. The program may be suspended or discontinued at any time and does not obligate the company to acquire any specific number of shares of its common stock. As part of the stock repurchase program, the Company intends to enter into a trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The 10b5-1 trading plan would permit common stock to be repurchased at a time that the Company might otherwise be precluded from doing so under insider trading laws or self-imposed trading restrictions. The 10b5-1 trading plan will be administered by an independent broker and will be subject to price, market volume and timing restrictions.

16:11 EST ResMed CEO Mick Farrell appointed chair of board - ResMed announced ResMed's board of directors has appointed chief executive officer Michael Farrell as chair of the board, effective January 25. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member. Mick Farrell became ResMed's CEO on March 1, 2013, and has served as a member of the company's board of directors since assuming that role.

16:07 EST Liminal BioSciences announces 10-for-1 reverse stock split - Liminal BioSciences announced that a consolidation of all of the issued and outstanding common shares of the company on the basis of a consolidation ratio of ten pre-consolidation common shares for one post-consolidation common share will become effective at the opening of trading on February 1. The company's current trading symbol will remain unchanged. The consolidation was previously approved by the company's shareholders at the special meeting of the shareholders held on January 20.

16:05 EST Wintrust Financial boosts dividend 17.6% to 40c per share from 34c - Wintrust Financial announced that the Company's Board of Directors approved a quarterly cash dividend of 40c per share of outstanding common stock. The dividend is payable on February 23 to shareholders of record as of February 9. This represents an increase of approximately 17.6% from the 34c quarterly cash dividend paid in each of the quarters of 2022. Additionally, the Company's Board of Directors approved quarterly cash dividends on outstanding shares of the Company's 6.50% Fixed-to-Floating Non-Cumulative Perpetual Preferred Stock, Series D and of the Company's 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E. Each dividend is payable on April 15, 2023 to shareholders of record as of April 1.

16:03 EST FormFactor opens new product demonstration, training center in California - FormFactor announced the opening of a new product demonstration and training center in San Jose, California. The facility is staffed with applications engineers and training professionals, and features FormFactor engineering wafer probers, metrology systems and advanced probe cards outfitted to meet semiconductor test and measurement requirements from lab to fab, including solutions for advanced packaging, automotive high-power devices, high-speed digital, silicon photonics, and 5G/6G/millimeter-wave mobile devices.

15:47 EST Insight Acquisition Corp trading resumes

15:41 EST Spotify tweets 'everything's looking much better now' - After having earlier this afternoon tweeted from its official status Twitter account: "Something's not quite right, and we're looking into it," Spotify now tweeted: "Everything's looking much better now! Get in touch with @SpotifyCares if you still need help." Reference Link

15:03 EST Bed Bath & Beyond says 'events of default' triggered on or around Jan. 13 - In its quarterly filing, Bed Bath & Beyond stated: "The Company's net cash used in operating activities was $307.6 million and $890.0 million for the three and nine months ended November 26, 2022. Cash, cash equivalents and restricted cash were $225.7 million as of November 26, 2022. On or around January 13, 2023, certain events of default were triggered under the Company's Credit Facilities (as defined below) as a result of the Company's failure to prepay an overadvance and satisfy a financial covenant, among other things. As a result of the continuance of such events of default, on January 25, 2023, the administrative agent under the Amended Credit Agreement notified the Company that (i) the principal amount of all outstanding loans under the Credit Facilities, together with accrued interest thereon, the FILO Applicable Premium (as defined in the Amended Credit Agreement) and all fees (including, for the avoidance of doubt, any break funding payments) and other obligations of the Company accrued under the Amended Credit Agreement, are due and payable immediately, (ii) the Company is required, effective immediately, to cash collateralize letter of credit obligations under the Credit Facilities, and (iii) effective as of January 25, 2023, all outstanding loans and obligations under the Credit Facilities shall bear interest at an additional default rate of 2% per annum. As a result of these events of default, the Company classified its outstanding borrowings under its asset-based revolving credit facility (the "ABL Facility) and its FILO Facility as current in the consolidated balance sheet as of November 26, 2022. The Company's outstanding borrowings under its ABL Facility and FILO Facility were $550.0 million and $375.0 million, respectively, as of November 26, 2022... At this time, the Company does not have sufficient resources to repay the amounts under the Credit Facilities and this will lead the Company to consider all strategic alternatives, including restructuring its debt under the U.S. Bankruptcy Code. The Company is undertaking a number of actions in order to improve its financial position and stabilize its results of operations including but not limited to, cost cutting, lowering capital expenditures, and reducing its store footprint including related distribution centers. In addition, the Company will continue to seek reductions in rental obligations with landlords in its determination of the appropriate footprint, seek additional debt or equity capital, reduce or delay the Company's business activities and strategic initiatives, or sell assets. These measures may not be successful."

14:51 EST Bed Bath & Beyond falls after warning on bankruptcy potential in 10-Q filing - In the quarterly filing, Bed Bath & Beyond stated: "At this time, the Company does not have sufficient resources to repay the amounts under the Credit Facilities and this will lead the Company to consider all strategic alternatives, including restructuring its debt under the U.S. Bankruptcy Code. The Company is undertaking a number of actions in order to improve its financial position and stabilize its results of operations including but not limited to, cost cutting, lowering capital expenditures, and reducing its store footprint including related distribution centers. In addition, the Company will continue to seek reductions in rental obligations with landlords in its determination of the appropriate footprint, seek additional debt or equity capital, reduce or delay the Company's business activities and strategic initiatives, or sell assets. These measures may not be successful." Previously, on January 5, Bed Bath & Beyond stated: "While the company continues to pursue actions and steps to improve its cash position and mitigate any potential liquidity shortfall, based on recurring losses and negative cash flow from operations for the nine months ended November 26, 2022 as well as current cash and liquidity projections, the company has concluded that there is substantial doubt about the company's ability to continue as a going concern. The company continues to consider all strategic alternatives including restructuring or refinancing its debt, seeking additional debt or equity capital, reducing or delaying the company's business activities and strategic initiatives, or selling assets, other strategic transactions and/or other measures, including obtaining relief under the U.S. Bankruptcy Code. These measures may not be successful." Reference Link

14:02 EST Bank of South Carolina says Hassell to retire as President and CEO on Sept. 30 - The Bank of South Carolina Corporation announced that Fleetwood Hassell plans to retire as President and Chief Executive Officer of the company and its subsidiary, The Bank of South Carolina, on September 30. Hassell will continue to serve on the board of directors of both the company and the bank after his retirement. The board of directors of the company and the bank have elected Eugene Walpole, IV, the current Executive Vice President & Chief Financial Officer, to succeed Hassell as President and CEO of the company and the bank effective October 1.

13:40 EST Danone exploring potential sale of Horizon Organic, Wallaby - Danone announced it will explore strategic options, including a potential sale, for its organic dairy activity in the U.S., comprised of the Horizon Organic and Wallaby businesses. The brands represent approximately 3% of Danone's global revenues and had a dilutive impact on Danone's like-for-like sales growth and recurring operating margin in 2022. Antoine de Saint-Affrique, Chief Executive Officer, said: "Both Horizon Organic and Wallaby are strong, much-loved brands with compelling growth opportunities. That said, seen through the lens of our Renew Strategy which requires us to stay disciplined in how we allocate our resources, they fall outside our priority growth areas of focus. We are confident that exploring strategic options for these brands will enable them to get the focus and resources they need and therefore allow them to maximize their potential and unlock further growth."

13:20 EST AstraZeneca continuing to work with FDA to collect data on Evusheld and variants - AstraZeneca issued the following update on U.S. Food and Drug Administration Emergency Use Authorization of Evusheld: "The US Food and Drug Administration has stated that AstraZeneca's Evusheld is not currently authorised for Emergency Use for pre-exposure prophylaxis of COVID-19 in the US until further notice, due to the sustained high frequency of circulating SARS-CoV-2 variants that Evusheld does not retain in vitro neutralisation against. The FDA has notified AstraZeneca that the Agency will make a determination about reinstating authorisation of Evusheld if the national prevalence of resistant variants decreases to 90% or less on a sustained basis. The US government recommends all Evusheld product be retained and properly stored in the event that variants susceptible to Evusheld, including those currently circulating at lower prevalence, become more prevalent in the future. Based on in vitro pseudovirus assay laboratory data, Evusheld does not neutralise Omicron subvariants BQ.1, BQ.1.1, BF.7, BF.11, BA.5.2.6, BA.4.6, BA.2.75.2, XBB and XBB.1.5. The combined proportion of COVID-19 cases caused by these subvariants is currently greater than 90% in the US, according to the Centers for Disease Control and Prevention Nowcast modelling data. AstraZeneca will continue to work with the FDA and other health authorities to collect, assess and share relevant data regarding Evusheld and SARS-CoV-2 variants. Evusheld currently remains authorised in other countries where it is approved for COVID-19 pre-exposure prophylaxis and treatment, including the EU and Japan. AstraZeneca has initiated the SUPERNOVA Phase I/III trial to investigate the safety and efficacy of a next-generation long-acting antibody in COVID-19 pre-exposure prophylaxis in an immunocompromised population. In in vitro lab studies, the new LAAB has been shown to neutralise all SARS-CoV-2 variants tested to date, including variants that have proved resistant to other monoclonal antibodies.3 AstraZeneca is aiming to make the new LAAB available in the second half of 2023, subject to trial readouts and regulatory reviews. About 2% of the global population is considered at increased risk of an inadequate response to COVID-19 vaccination and could benefit from monoclonal antibodies for COVID-19 protection." Reference Link

13:01 EST WiSA Technologies announces 1-for-100 reverse stock split - WiSA Technologies announced that on January 24, 2023 the Company's Board of Directors approved a 1-for-100 reverse split of the Company's common stock. On January 26, 2023, the Company filed a certificate of amendment to the Company's certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split as of 5:00 p.m. Eastern Time on that date. On January 26, 2023, the Common Stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis at the start of trading on January 27, 2023 and will have a new CUSIP number of 86633R302.

13:01 EST Aptevo CFO expects preliminary data readout from 527 trial in second half

13:00 EST Aptevo sees potential for multiple data readouts in 2023, CFO says

12:59 EST Southwest says it continues to experience year-over-year inflationary pressures - Sees H2 CASM-ex trends improving. Says doesn't expect to be caught up on MAX deliveries by the end of this year.

12:39 EST FDA announces Evusheld not currently authorized for emergency use in U.S. - The U.S. Food and Drug Administration revised the Emergency Use Authorization, or EUA, for Evusheld to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, Evusheld is not currently authorized for use in the U.S. until further notice by the agency, the FDA announced. "Data show Evusheld is unlikely to be active against certain SARS-CoV-2 variants. According to the most recent CDC Nowcast data, these variants are projected to be responsible for more than 90% of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants. Today's action to limit the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions, which can be potentially serious, at a time when fewer than 10% of circulating variants in the U.S. causing infection are susceptible to the product," the FDA stated in a notice posted to its website. Reference Link

12:01 EST Interpublic Group names Jeriad Zoghby as chief commerce strategy officer - Interpublic Group announced that Jeriad Zoghby is joining the company as Chief Commerce Strategy Officer. In his role, Zoghby will oversee commerce strategy for the holding company, connecting the existing channel and platform expertise across the IPG portfolio and helping to identify opportunities for further growth. Zoghby starts immediately, the company said.

12:00 EST Paragon 28 falls -16.6% - Paragon 28 is down -16.6%, or -$3.33 to $16.75.

12:00 EST Applied Industrial Technologies rises 11.2% - Applied Industrial Technologies is up 11.2%, or $13.75 to $136.24.

12:00 EST Boot Barn rises 12.3% - Boot Barn is up 12.3%, or $9.15 to $83.53.

11:33 EST Verb Technology reports paying off senior secured convertible debt in full - Verb Technology announces that it has paid off its senior secured convertible debt in full, in cash, and cancelled its equity line of credit, or "ELOC." On January 12, 2022, the company entered into a securities purchase agreement with three institutional investors providing for the sale and issuance of an aggregate original principal amount of $6.3M in convertible notes due 2023. The company and the note holders also entered into a security agreement, dated January 12, 2022 in connection with the note offering, pursuant to which the company granted a security interest to the note holders in substantially all of its assets. Pursuant to the terms of the securities purchase agreement, the notes have been paid in full, in cash, prior to any conversion. In addition, on January 12, 2022, the company entered into a common stock purchase agreement with an institutional investor. Pursuant to the common stock purchase agreement, the company had the right, but not the obligation, to sell to the Investor, up to $50M of newly issued shares of the company's common stock, subject to certain limitations and conditions. The company has exercised its right to terminate the common stock purchase agreement effective immediately by mutual agreement of the parties, Verb announced.

11:27 EST Petrobras approves election of CEO Jean Paul Terra Prates - Petrobras has informed that its Board of Directors, in a meeting held today, unanimously, appointed Mr. Jean Paul Terra Prates as Petrobras' Director, until the next General Shareholders' Meeting, and elected him as the company's CEO, the latter with a mandate until 04/13/2023, the same term of office of the other members of Petrobras' Executive Board. Reference Link

11:16 EST HUB Cyber Security announces expected SPAC merger date - HUB Cyber Security Ltd announced that following the receipt of all approvals and compliance with the conditions for the expected merger with Mount Rainier Acquisition Corp. and transition to trading on the Nasdaq stock exchange, that the details of the expected procedure for the listing in the United States will be as follows: On February 27, the merger with RNER is expected to occur and official announcement of the closing of the merger will be publicized. On February 28, the first expected day of trading of the company's shares on Nasdaq under the symbol "HUBC."

11:01 EST FB Financial raises dividend by 15% to 15c per share - FB Financial announced that its board of directors declared a quarterly cash dividend of 15c per share. The dividend is payable on February 21 to shareholders of record as of February 7. Christopher Holmes, President and CEO, commented, "We are pleased with the board of directors' decision to pay our 20th consecutive quarterly dividend and are happy to be able to increase the dividend by 15% compared to prior quarters. We remain committed to building long-term shareholder value by returning a portion of the company's earnings to shareholders through cash dividends."

10:47 EST Scilex Holding Co trading halted, volatility trading pause

10:33 EST F star Therapeutics trading resumes

10:27 EST Valero sees FY23 capital investments $2B - Comments taken from Q4 earnings conference call.

10:08 EST BAER Stock trading halted, volatility trading pause

10:06 EST Armada Acquisition Corp I trading resumes

10:01 EST Armada Acquisition Corp I trading halted, volatility trading pause

10:00 EST MarineMax falls -8.9% - MarineMax is down -8.9%, or -$3.09 to $31.60.

10:00 EST Paragon 28 falls -15.5% - Paragon 28 is down -15.5%, or -$3.12 to $16.96.

10:00 EST Applied Industrial Technologies rises 9.6% - Applied Industrial Technologies is up 9.6%, or $11.75 to $134.24.

09:58 EST Northrop Grumman says 'performing exceptionally well' on B-21 program - Says foundation set for strong free cash flow in second half of the decade.

09:58 EST Nemaura Medical receives first purchase order from HealthFleet - Nemaura Medical announced receipt of a first purchase order for 5,000 proBEAT subscriptions from HealthFleet, a telehealth provider focusing on care, coaching, and health recommendations. The purchase order consists of 75,000 proBEAT glucose sensors over an initial five month period and is valued at $500,000 in revenue. HealthFleet has an option to increase volumes based on customer response.

09:55 EST Alvarium Tiedemann Holdings Inc trading resumes

09:50 EST Alvarium Tiedemann Holdings Inc trading halted, volatility trading pause

09:47 EST Sherwin-Williams falls -10.7% - Sherwin-Williams is down -10.7%, or -$26.42 to $220.67.

09:47 EST LendingClub falls -14.1% - LendingClub is down -14.1%, or -$1.46 to $8.88.

09:47 EST DoubleVerify rises 8.9% - DoubleVerify is up 8.9%, or $2.26 to $27.70.

09:41 EST Hancock Whitney increases quarterly dividend 11%, renews share buyback program - Hancock Whitney announced that at its January meeting, the company's board of directors approved a regular first quarter 2023 common stock cash dividend of 30c per common share, an increase of 3c per common share, or 11%. The first quarter dividend is payable on March 15 to shareholders of record as of March 6. Additionally, during the January meeting, the board authorized a stock buyback program pursuant to which the company may, from time to time, purchase up to 4,297,000 shares of its outstanding common stock, replacing the previous stock buyback program that expired on December 31, 2022.

09:38 EST SJW Group increases quarterly dividend 5.6% to 38c per share - The board of SJW Group has declared a quarterly cash dividend of 38c per share payable on March 1 to all shareholders of record at the close of business on February 6. The March dividend will represent a 5.6% increase over the dividend paid in December 2022. The 2023 annualized dividend will be $1.52 per share compared with $1.44 per share in 2022.

09:32 EST Azul, FLYR Labs partner on revenue optimization initiatives - FLYR Labs announced a new partnership with Brazilian airline Azul to deploy FLYR's advanced AI technologies as a way to optimize the airline's revenue management strategy, starting with fare bundles and ancillary product optimization, helping to meet a growing variety of customer demands. To help Azul achieve its goal of enabling total revenue management and dynamic offer optimization, FLYR will provide Azul with comprehensive data management, pricing, and forecasting capabilities that enable tailored offers for Azul's customers.

09:28 EST Coya data supports role of T-cells for disease modification in Alzheimer's - Coya Therapeutics announced the recent publication of an article entitled "Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's Disease" in the peer reviewed journal Acta Neuropathologica Communications. The preclinical study was conducted by Ali Faridar, M.D., of Houston Methodist Hospital , under the leadership of Stanley Appel, M.D., the chair of Coya's Scientific Advisory Board. "These data further support that enhancing Treg function is a potential strategy to ameliorate neuroinflammation, which may modify Alzheimer's Disease-associated pathology in the brain. Coya intends to enter a Phase I clinical trial of Treg enhancing biologics for the treatment of neurodegenerative diseases in 2023 with interim data readout anticipated by or before Q1 2024," stated Howard Berman, Ph.D., Chief Executive Officer of Coya. "We continue advancing our product candidate pipeline including our biologic programs, which are intended to enhance Treg function in vivo and we believe have the potential to address the significant unmet needs of patients with serious neurodegenerative diseases," stated Dr. Berman.

09:23 EST Diana Shipping announces direct continuation of time charter contract - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has extended the time charter contract with Aquavita International S.A., for one of its Ice Class Panamax dry bulk vessels, the m/v Atalandi. The gross charter rate is $13,250 per day, minus a 4.75% commission paid to third parties, for a period until minimum March 5, 2024 up to maximum May 5, 2024. The new charter period is expected to commence on February 15, 2023. The "Atalandi" is a 77,529 dwt Ice Class Panamax dry bulk vessel built in 2014. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Cargill International S.A., Geneva, for one of its Panamax dry bulk vessels, the m/v Leto. The gross charter rate is $14,500 per day, minus a 4.75% commission paid to third parties, for a period until minimum March 1, 2024 up to maximum April 30, 2024. The charter is expected to commence by the end of January of 2023. The "Leto" is a 81,297 dwt Panamax dry bulk vessel built in 2010. The employment extension of "Atalandi" as well as the employment of "Leto" are anticipated to generate approximately $10.68 million of gross revenue for the minimum scheduled period of the time charters.

09:22 EST Northrop Grumman says entering 2023 with strong backlog of $79B - Says converting backlog into revenue at "accelerating rate." Says defense budgets on the rise, meeting customer needs. Expects to grow international business over next few years. Says well-positioned for growth in 2023. Expects solid margins, strong free cash flow growth in 2023. Expects to return at least 100% of adjusted free cashflow to shareholders in 2023. Expects Space Systems to be fastest growing business in 2023. Expects 1Q sales to represent 24% of FY guidance. Expects 2024 & 2025 growth driven by: Operational performance; Lower R&D cash tax payments; Higher CAS recoveries: Lower Capex, particularly in 2025. Comments taken from Q4 earnings conference call.

09:18 EST Lakeland Industries finalizes board transitions - Lakeland Industries announced that Christopher Ryan, Executive Chairman of the Board, has announced his retirement as an employee of Lakeland Industries and will step down from his role as Executive Chairman, effective January 31, 2023. Mr. Ryan will remain a member of the Board of Directors of Lakeland until completion of his term at the Annual Shareholders Meeting, June 14, 2023, as was previously announced in the Company's June 2022 press release. Effective February 1, 2023, consistent with the Board's succession plan, current member of the Board and Vice Chairman, James Jenkins, will assume the role of Chairman of the Board of Lakeland Industries, Inc.

09:16 EST H&R Block launches AI technology to find Americans tax refunds - H&R Block announces the launch of new artificial intelligence-powered technology that automatically searches customers' last year TurboTax return for additional refunds when they switch and file a return this year using H&R Block's Online DIY product. In initial modeling, this industry-first approach identified millions in additional refunds in last year's returns filed with TurboTax.

09:11 EST O-I Glass offers first look at MAGMA operations - O-I Glass released a video offering a first look at existing MAGMA operations as the company prepares for its first, purpose-built MAGMA factory in Bowling Green, KY. The video combines live footage of MAGMA lines with insight as to the transformational nature of the new technology. "MAGMA will set new standards in glass manufacturing, allowing us to use renewable sources of energy and more recycled content, while reducing greenhouse gas emissions and waste," said Ludovic Valette, O-I VP of Global Technology and Engineering. "It provides scalability and rapid deployment, as well as lower capital intensity, mobility, flexibility, and consequently supply chain efficiency." O-I recently announced the construction of a new greenfield glass plant in Bowling Green, KY that will be the first facility purposely built for the revolutionary MAGMA technology. Enabled by advanced technologies and innovative processes, the state-of-the-art site is expected to come on stream mid 2024 and further enhance O-I's customer service, flexibility, and sustainability.

09:10 EST GitLab continues expanding security certification, report portfolio - GitLab announced the successful expansion of its security certification and report portfolio. GitLab received a SOC 2 Type 1 report for the recent GitLab Dedicated solution, which includes Security and Confidentiality criterion, and expanded its SOC 2 Type 2 report for GitLab.com to include the Availability Criteria. GitLab also expanded its ISO/IEC 27001:2013 certification scope to include the GitLab Dedicated solution, and received a certification expansion against the ISO/IEC 27017:2015 for cloud security standards and ISO/IEC 27018:2019 privacy standards1. In addition, GitLab Dedicated was included in the ISO/IEC 27001:2013 certification scope. GitLab Dedicated offers a new deployment option by making our DevSecOps platform available as a single-tenant SaaS solution. GitLab Dedicated allows organizations to leverage the efficiency of the cloud while further enabling customers to meet their own regulatory expectations in a completely isolated instance.

09:10 EST Centessa announces FDA clearance of IND to initiate Phase 1/2a study of LB101 - Centessa Pharmaceuticals announced that it has received clearance of its Investigational New Drug, IND, application from the U.S. Food and Drug Administration, FDA, to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors. LB101 is the first product candidate developed using the Company's proprietary LockBody technology. "We are very excited to be bringing our first LockBody candidate to the clinic and to be advancing a potentially transformative technology for patients with solid tumors," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "The clearance of our IND for LB101 is an important milestone for our company as we have an ambitious strategy to advance multiple potential LockBody candidates in areas where there is a significant need for new cancer treatment options. We look forward to initiating the Phase 1/2a trial of LB101 as soon as possible."

09:08 EST Matterport to provide digital twin platform for John Deere - Matterport (MTTR) announced that John Deere (DE) has agreed to use Matterport's Digital Twin Platform and 3D capture technology to build a virtual Operations Center for remote management of over 60 facilities across North America, South America, Europe and Asia. Matterport's platform creates simulated digital replicas of John Deere manufacturing facilities, where teams can remotely track progress, plan for site changes, and collaborate remotely. Utilizing Matterport's Pro2 and Pro3 cameras, John Deere will capture spatially accurate, 4K resolution digital twins to optimize facility operations. "We're proud to support John Deere on their journey to reinvent manufacturing operations," said Jay Remley, Matterport's Chief Revenue Officer. "For global businesses with facilities spread across several regions and time zones, the ability to remotely optimize each space based on its own unique parameters is a critical unlock for operations management. Our digital twin platform enables companies to reap real productivity gains and cost savings by digitizing their operations for more efficient maintenance, remote monitoring and improved decision making."

09:07 EST GE, Sound Technologies partner to distribute Vscan Air to veterinarians - GE HealthCare and Sound Technologies, the global veterinary imaging leader announced an agreement to distribute the Vscan Air, a cutting-edge, wireless pocket-sized ultrasound that provides crystal clear image quality, whole-patient scanning capabilities, and intuitive software - to veterinary practices in the United States. Ultrasound applications in veterinary care present the opportunity to transform healthcare for dogs, cats, horses, cows, pigs, goats and exotic animals including small mammals and reptiles. Ultrasound enables the examination of internal organs in precise detail without the risk of ionized radiation and is generally inexpensive. It is an important tool in veterinary medicine as it allows vets to diagnose a range of conditions that animals are susceptible to and enables vets to examine internal organs in precise detail, unlike X-rays that typically provide an overall picture of the area.

09:06 EST Sono Motors extends community campaign until February 28 - Sono Group announced an extension of its special community campaign. More than EUR 47 million has been committed in the #savesion campaign from over 8,600 community members and other sources since early December. The ongoing campaign underscores the uniqueness of Sono Motors as a true community brand. Before the start of the campaign, Sono Motors had already received in total approximately 21,000 private reservations with advance payments. During the campaign, Sono Motors received over 1,500 new private reservations with deposit commitments. The campaign began on 8 December 2022 and will now be extended by approximately one month to 28 February 2023. In response to demand, Sono Motors also announced 12 additional stops for the Sion tour, which already enabled approximately 5,000 people in 13 different European cities to get a first-hand experience of the Sion - Sono Motors' affordable solar electric vehicle. The goal of the campaign is to raise approximately EUR 105 million. If the goal is not achieved, Sono Motors currently intends to halt the development of the Sion and will instead focus on its solar technology business, which is significantly less capital intensive. In addition, Sono Motors recently secured EUR 1.46 million in funding from the European Climate, Infrastructure and Environment Executive Agency to advance the development of the Company's proprietary solar technology, further evidencing the Company's in-depth technological expertise and knowledge. While the campaign has progressed, the Company has been also making significant progress on its testing and series-validation program for the Sion, remaining on track technologically to start pre-series production in the summer of 2023.

09:04 EST Abbott: FDA approves Proclaim XR spinal cord stimulation system - Abbott announced that the U.S. FDA has approved its Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral neuropathy, a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.

09:03 EST Medigus says Gix increases holdings in Cortex Media Group - Medigus announced that Gix Media, a subsidiary of Medigus affiliate, Gix Internet, acquired an additional 10% of Cortex Media Group, a digital publishing company, increasing its holdings to 80% of the share capital of Cortex on a fully diluted basis. The Subsequent Purchase was completed at a valuation of Cortex of approximately $27 million in exchange for consideration consisting of $2.7 million in cash. The Subsequent Purchase follows Gix Media's initial purchase of 70% of Cortex's share capital in October 2021. At the Initial Purchase, Cortex was valued at $16 Million and the increase in Cortex's current valuation is primarily due to an increase in its results and activity and its improved financials. During the period following Gix Media's Initial Purchase, Gix Media's revenues grew by 176% to $66.1 million during the nine months ending September 30, 2022, as compared to the same period in 2021. Gix Media intends to finance the Subsequent Purchase through both cash and the expansion of a $1.5 million loan.

09:02 EST Cullen/Frost reports Q4 EPS $2.91, consensus $2.75 - The net interest margin was 3.31% for the fourth quarter of 2022 compared to 2.31% for the fourth quarter of 2021 and 3.01% for the third quarter of 2022.

08:54 EST State Street engages Amazon and Microsoft for cloud in 'transformation journey' - State Street (STT) announced that it has engaged both Amazon Web Services, AWS. (AMZN) and Microsoft (MSFT) as strategic providers of cloud and infrastructure solutions in connection with its multi-year technology transformation journey. State Street is consolidating its current network of segregated data center facilities to a more optimized data center footprint with fit-for-purpose designed and managed facilities. Through this transformation, State Street will modernize and standardize its technology infrastructure, leveraging automation and a combination of private cloud and public cloud capabilities. This hybrid and hyperconverged model combines all the elements of a traditional data center, storage, compute, networking and management, and will allow State Street to host workloads across private or public environments to optimize agility, performance, and scalability. This model will enable accelerated migration and modernization of applications, with the flexibility to accommodate strategic integrations. As part of its ongoing technology transformation journey, State Street's focus on modernization through the facility, infrastructure, and application stack will increase resiliency, enable rapid business product innovation, and deliver enhanced customer experiences. To advance its strategy and accelerate its technology transformation, State Street has entered into strategic engagements with leading cloud providers.

08:52 EST American Airlines sees FY23 CASM-ex up 2%-5% vs. FY22 - Sees total unit revenue up low single digits y/y. Sees industry revenue returning to historical share of GDP in 2023. Sees operating cash flow approximately $5.5B, free cash flow of nearly $3B.

08:49 EST NeoVolta expects California's NEM program to drive increased demand - NeoVolta expects California's recently updated Net Energy Metering program to drive increased demand for energy storage systems. On December 15, 2022, the California Public Utilities Commission issued a decision to update the NEM tariff to promote consumer adoption of solar and battery storage. The program will go into effect on April 13, 2023. According to the CPUC, the move was designed to financially incentivize Californians to install both battery and solar systems. The CPUC stated that the current NEM 2.0 program was not aligned with California's grid reliability and climate goals, noting that the increased use of electricity between 4 and 9 p.m. causes dependence on fossil fuel gas plants to meet the demand. With the battery storage incentive, the CPUC hopes to see an increased adoption of residential energy storage that will better support the needs of the grid, with customers saving self-generated solar energy for use in the evening hours. An additional $630 million in state funding has been set aside by the California State Legislature for residential low-income solar plus battery storage adopters. The decision bolsters federal incentives provided by the Inflation Reduction Act for solar and battery storage.

08:47 EST AdTheorent appoints Patrick Elliott as CFO - AdTheorent will appoint Patrick Elliott as CFO, effective January 30, succeeding Chuck Jordan, who has served as CFO or in other financial roles since 2017. Prior to joining AdTheorent, Elliott was Senior VP of Finance at Skillsoft, a global leader in education technology. Prior to this, Elliott spent nine years at Maxar Technologies, a leader in space technology, in various senior roles, most recently serving as Vice President, Financial Planning and Analysis & Corporate Development. Prior to his tenure with Maxar Technologies, Elliott held various financial positions at Ivory Capital, Ernst & Young, and Samuelson Partners.

08:43 EST American Resources says Kenai Defense signs contract with AFCEC - American Resources announces that Kenai Defense Company has secured a contract for the development of its exclusive patents with the Air Force Civil Engineering Center. This contract will call for Kenai Defense to work with the AFCEC to develop applications for the use of carbon nanostructures as a functional concrete additive.

08:42 EST Xcel Energy, Form Energy team to deploy iron-air battery systems - Form Energy announced that it has entered into definitive agreements with Xcel Energy to deploy its iron-air battery systems at two of Xcel Energy's retiring coal plant sites. The storage technology will allow Xcel Energy to integrate more low-cost, renewable energy into its system and maintain reliability as it retires the coal plants in the coming years and transitions to a highly renewable future. Xcel Energy-Minnesota will deploy a 10 MW / 1,000 MWh multi-day storage system at the Sherburne County Generating Station in Becker, Minnesota. Xcel Energy-Colorado will deploy a 10 MW / 1,000 MWh multi-day storage system at the Comanche Generating Station in Pueblo, Colorado. Both projects are expected to come online as early as 2025 and are subject to regulatory approvals in their respective states.

08:41 EST Constellation Brands announces Locke to retire from board of directors - Constellation Brands announced that James Locke III has informed the company that he will retire from the company's Board of Directors at the end of his current term and consequently will not stand for re-election as a Board Director at Constellation's upcoming Annual Shareholders Meeting in July 2023. Locke will also complete and retire from his current roles as Lead Independent Director of the Board and Chair of the Corporate Governance and Responsibility Committee at that time. Following the company's upcoming Annual Shareholders Meeting, Constellation's newly elected Board of Directors will identify successors for the Lead Independent Director of the Board and Chair of the Corporate Governance and Responsibility Committee roles as part of its first meeting.

08:40 EST Genasys receives $1.6M international bird, wildlife preservation order - Genasys announced a follow-on $1.6M LRAD systems order for bird and wildlife preservation. These systems will be integrated with award-winning DeTect MERLIN trailers that feature advanced avian radar for continuous monitoring, detecting, and deterring birds and wildlife from entering restricted areas."Our largest order from DeTect to date continues our 13-year partnership of protecting wildlife," said Richard Danforth, Chief Executive Officer, Genasys Inc. "When shipped, we will have delivered $10 million in LRAD orders to DeTect during our collaboration. As with previous orders, the integrated systems will be deployed at mining operations in northern Canada. International mining and oil & gas companies have purchased hundreds of these industry-leading systems that humanely detect and deter birds and wildlife from hazardous tailing ponds and waste areas."

08:39 EST Isom: American had best completion factor of any major U.S. airline

08:38 EST BetMGM reports FY22 revenue $1.44B - BetMGM, jointly owned by Entain and MGM Resorts (MGM) provided an update on performance and outlook for FY23. BetMGM finished FY22 with net revenue from operations of $1.44B, ahead of prior guidance of over $1.3B. Same-state growth in net revenue from digital operations was 51% in FY22. FY22 EBITDA loss was approximately $440M, in line with prior guidance. The company said, "Financial outperformance driven by: Higher gross gaming margins resulting from improved customer experience and other product improvements. Same state CPAs reduced by 21% year-over-year due to data-focused marketing strategy and increased scale. Improved approach to player bonusing delivered by our data science team."

08:38 EST Avantax announces appointment of Bailey as CLO, Corporate Secretary - Avantax announced that Tabitha Bailey has been appointed Chief Legal Officer, CLO, and Corporate Secretary, succeeding Ann Bruder, who has stepped down from her role as Chief Legal, Development and Administration Officer after nearly six years in the role. Bruder has agreed to continue to work with Avantax in a consulting role through the end of June to support the transition. Bailey joined Avantax in November 2020 as Vice President, Legal Affairs and SEC Counsel.

08:37 EST BTCS announces application for dual listing on Upstream - BTCS Inc. has begun the application process to dual list its shares of common stock on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. Approval to be listed on Upstream is subject to acceptance by MERJ. However, as an existing Nasdaq issuer, BTCS may be eligible for an expedited listing process.

08:36 EST Bone Biologics engages Avania as contract research organization for NB1 trial - Bone Biologics announces it has engaged Avania as the contract research organization CRO for the Company's pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic's novel NB1 in patients with degenerative disc disease undergoing a Transforaminal Lumbar Interbody Fusion procedure. This multicenter, parallel group, randomized trial is designed to evaluate the safety and preliminary effectiveness of NB1 bone graft in 30 subjects with degenerative disc disease undergoing a TLIF. The trial is expected to be initiated in the second half of 2023, pending approval from the Monash Health system ethics committee in Australia.

08:32 EST Duke Energy begins operation of Idaho's largest solar plant - Duke Energy Sustainable Solutions, a nonregulated commercial brand of Duke Energy, announced it has placed into commercial operation the 120-megawatt Jackpot Solar project in Twin Falls County, Idaho. This is the organization's first utility-scale renewable energy project in the state and is the largest solar facility in operation in Idaho. It will provide energy to Idaho Power through a 20-year power purchase agreement. At 120 megawatts of capacity, the plant will generate enough electricity annually to serve the energy needs of roughly 24,000 homes.

08:29 EST Biotricity signs distribution agreement with U.S. medical device distributor - Biotricity signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions designed for cardiologists' patient use - Bioflux and Biotres.The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients.

08:26 EST iVexSol closes $23.8M Series A-3 financing - iVexSol announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (BMY), Charles River Laboratories (CRL) and Asahi Kasei Medical, a division of Asahi Kasei (AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (BLFS) to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol's Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines.

08:22 EST Disney announces two-year expansion of partnership with Magnite - In a blog post titled "Automation and Identity Define The Future of Addressability," Disney (DIS) stated: "Two years ago, Disney had a bold ambition - lay the foundation for a fully automated and addressable future. This commitment called for a complete overhaul of Disney's advertising platform - one that would power the capability for advertisers to buy 'once' and deliver "anywhere" across Disney's vast portfolio of news, sports and entertainment brands. Since embarking on this journey, Disney invested in the innovation required to reimagine its ad server, unifying inventory across all properties, while putting programmatic automation front and center - and introducing parity across all marketplaces... Tools and technology built in-house, like the Disney Real-Time Ad Exchange (DRAX) and Disney's Unified Ad Platform created the ability for advertisers to reach the most valuable audiences for their business, with improved frequency tapping into real-time data signals. And the proof is in the performance - Disney Advertising has seen nearly a 150% rise in biddable, double the growth over last year for the programmatic business. The next phase of Disney's Addressable innovation lives at the intersection of identity and interoperability... By creating direct integrations to the Disney Audience Graph, whether through The Trade Desk for buying, VideoAmp, for precise measurement in connected TV, or Magnite, through a global, two-year expansion that increases access to CTV and mobile inventory, unlocking first-party identity at scale through automation is at the heart of Disney's Addressable advantage." Reference Link

08:20 EST Uniti Group signs long-haul dark fiber agreement with global internet provider - Uniti Group announced that it has signed a long-term contract with a large global internet provider, offering long-haul dark fiber connectivity to premier data centers located in 12 cities within the Central and Southeastern United States. The routes include El Paso, TX to San Antonio, TX, Indianapolis, IN to Nashville, TN, Nashville, TN to Atlanta, GA, Dallas, TX to Beaumont, TX, Houston, TX to Jacksonville, FL, Tallahassee, FL to Tampa, FL, and Miami, FL to Tampa, FL. The agreement provides scalable and secure transport over a combined 3,100 fiber route miles, connecting several Internet traffic aggregation points and key infrastructure hubs for Uniti's customer. The Houston, TX to Jacksonville, FL route will require Uniti to build ten new In-Line Amplifier, ILA, shelters where its customer will lease space and power to regenerate their optical signal. These locations will not only allow Uniti to lease additional space and power to other customers, but they will also allow Uniti to regenerate its own optical signal as it deploys its Private Wave Channel product along this route in the near future. "Today's announcement represents one of the largest customer contracts, by total contract value, in Uniti's history, encompassing over 10,600 fiber strand miles," said Greg Ortyl, President of Wholesale and Strategic Accounts. "This existing customer continues to demonstrate confidence in Uniti's ability to deliver unique, end-to-end infrastructure solutions that meet their increasing bandwidth demands. Furthermore, the new ILA shelters position us for incremental space and power lease-up and quicker deployment intervals of our PWC product when we commence the lighting of Houston to Jacksonville, allowing Uniti to offer 100G, 400G and spectrum services along this route."

08:19 EST Accenture invests in 3D holographic volumetric video tech firm Forma Vision - Accenture has made a strategic investment, through Accenture Ventures, in Forma Vision, a provider of live-streamed, volumetric video technology that enables 3D holographic images of people, objects and environments to be beamed into the metaverse from any office, home or other Until now, the metaverse opportunity has been constrained to enterprise use cases appropriate for avatar-to-avatar interactions. Now, using Forma Vision's low-cost, live-streaming volumetric video technology, enterprises of any size can teleport people, places and things into their metaverse experience. For example, Accenture and others have conducted executive town-halls, training, and small group meetings using Forma Vision. "Accenture sees the metaverse as an evolving and expanding continuum of technologies that will increasingly blur the boundary between the physical and the digital and transform the way businesses and consumers interact," said David Treat, senior managing director and global lead of Accenture's Metaverse Continuum business group. "We believe Forma Vision's volumetric video technology will enable more immersive, engaging interactions and help further bridge real and virtual worlds by allowing people, places and things to be more authentically represented in the metaverse."

08:17 EST Driven Brands promotes Danny Rivera to new COO position - Driven Brands appointed Danny Rivera to the newly-created role of COO effective February 20. Mo Khalid will succeed Rivera in the role of Executive VP & Group President, Maintenance, leading both Take 5 Quick Lube and Meineke. Rivera has more than 20 years of experience in the consumer and retail category, most recently serving as Executive VP & Group President, Maintenance, and earlier in a number of executive positions, including serving as the company's Chief Information Officer and President of Meineke. Prior to joining Driven Brands in 2012, he served in a variety of leadership roles at AutoNation, Burger King, General Electric, and Motorola. Khalid is joining Driven Brands from his most recent role as Senior VP, Field Operations, at Great Wolf Resorts. Previously, he served as the VP and COO of Meineke at Driven Brands.

08:17 EST Alta Fox sends letter to Daktronics board on leadership change, liquidity help - Alta Fox letter read as follows: "Alta Fox Capital Management is now the largest shareholder of Daktronics with ownership of more than 5.8% of the Company's outstanding common shares. While we commend the Strategy and Financing Review Committee of the Board of Directors for securing a credit agreement amendment, we are extremely disappointed that it is not taking decisive action to address deep-rooted issues related to the Company's corporate governance, management team and value creation efforts. We believe these long-standing issues culminated in the Company's auditor issuing "substantial doubt about the Company's ability to continue as a going concern," as disclosed in the recent 8-K filed with the SEC. Alta Fox has been adamant about the urgent need for governance improvements, leadership changes and an immediate and certain liquidity solution during our private interactions with the Board, but no substantive changes have been made. Therefore, it is with deep regret that we have to file a Schedule 13D this week without being able to disclose a cooperation agreement with Daktronics or any indication of a productive relationship with you-the very individuals whom the Company's stakeholders are depending on to protect them from further Kurtenbach-driven missteps, nepotism and value destruction. Daktronics has seen its equity market capitalization decline by hundreds of millions of dollars during the tenure of Chairman and Chief Executive Officer Reece Kurtenbach, making your apparent loyalty to the Kurtenbach family and resistance to Alta Fox's good faith engagement truly confounding."

08:16 EST Wejo announces first milestone in TKB Critical Technologies 1 combination - Wejo (WEJO) announced the first milestone in its proposed business combination with TKB Critical Technologies 1 (USCT). TKB was able to retain approximately $53M in its trust account following the redemption deadline for the Class A ordinary shares issued in TKB's IPO in connection with TKB's extraordinary general meeting seeking shareholder approval of an extension of the date by which TKB must consummate an initial business combination. TKB shareholders may request to withdraw redemptions at any time until the vote is taken with respect to the extension.

08:15 EST Boeing selected to produce Next Generation Automated Test System by U.S. Army - The company states: "The U.S. Army has selected Boeing to produce additional Next Generation Automated Test System, NGATS, units with a contract award worth up to $92 million over three years. NGATS is a single, mobile diagnostic tool that provides real-time testing in the field. NGATS provides immediate solutions, enabling automated fault diagnosis of more than 100 components. NGATS eliminates manual troubleshooting and disassembly of components which reduce labor hours. NGATS aids in avoiding lead times that come with ordering parts and possible depot-level maintenance. One Armored Brigade Combat Team noted NGATS saved more than $26 million in repair costs in five months. In addition to Army platforms such as the M1A2 SEP V2/V3/V4, M1A1 Abrams tank, M2A3 Bradley, and M1126 Stryker vehicles, these versatile units will be used in 2023 on M109A7 Paladin and the UH-60 Black Hawk helicopters. A similar test program set is being developed by Boeing to address no evidence of failure issues while maintaining readiness on the AH-64 Apache."

08:14 EST Ventyx Biosciences announces pipeline updates, strategic priorities - Ventyx Biosciences is hosting an investor R&D Day today highlighting key aspects of Ventyx's clinical-stage and discovery programs. Pipeline Updates and Anticipated Catalysts: VTX958:Enrollment is ongoing in the Phase 2 SERENITY trial of VTX958 in moderate-to-severe plaque psoriasis and the Phase 2 HARMONY trial in Crohn's disease, while screening activities have initiated for the Phase 2 TRANQUILITY trial in psoriatic arthritis. Topline data from the Phase 2 SERENITY psoriasis trial are anticipated in Q4 2023. Topline readouts from the Phase 2 HARMONY and Phase 2 TRANQUILITY trials are expected in 2024. VTX002: Ventyx continues to make significant progress enrolling the Phase 2 trial of VTX002 in moderate-to-severe ulcerative colitis. Ventyx expects to complete enrollment by mid-2023, and topline results are anticipated in the second half of 2023. VTX2735: Ventyx is presenting additional data from the completed Phase 1 trial of VTX2735 in healthy volunteers, in which VTX2735 demonstrated excellent safety and target coverage. VTX2735 was well tolerated across all doses tested, with anticipated Phase 2 dose regimens expected to achieve IC90 coverage of IL-1beta for 20 hours or more. A Phase 2 proof-of-mechanism trial of VTX2735 in cryopyrin-associated autoinflammatory syndromes is expected to initiate in Q1 2023. VTX3232: Ventyx expects to file an IND and initiate a Phase 1 trial for VTX3232 during the first half of 2023. The Phase 1 trial is expected to characterize the safety, target engagement and bioavailability of VTX3232 in the central nervous system of healthy volunteers. Discovery Programs: Ventyx is introducing a new discovery-stage program focused on small molecule antagonists of IL-4Ralpha, a target validated by biologics in multiple large autoimmune indications, including atopic dermatitis, asthma and eosinophilic esophagitis. Ventyx is advancing multiple internally discovered novel chemical series through lead optimization with the goal of establishing in vivo proof-of-concept and nominating a lead candidate in 2023.

08:11 EST Soleno Therapeutics announces publication of results from Phase 3 trial of DCCR - Soleno Therapeutics announced that results from the Company's previously completed Phase 3 DESTINY PWS trial of DCCR Extended-Release tablets for the treatment of Prader-Willi Syndrome have been published in a peer-reviewed journal. The article, entitled, "Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial," was published in The Journal of Clinical Endocrinology and Metabolism. "We are pleased that the data from the C601 study of DCCR in PWS have been published in a prestigious peer-reviewed journal, JCEM," said Anish Bhatnagar, M.D., CEO of Soleno Therapeutics. "Based on the promising results from the trial, as well as discussions with the U.S. Food and Drug Administration, we initiated a randomized withdrawal period of the open-label Phase 3 extension study C602, which has the potential to support the submission of a New Drug Application. Trial subjects are currently being randomized at our clinical sites."

08:09 EST Merck Animal Health announces FDA approval for Bravecto Chews for Dogs - Merck Animal Health, a division of Merck & Co., announced the FDA's approval of an expanded indication for Bravecto Chews for Dogs. The new indication treats and controls Asian longhorned ticks, which are an invasive Ixodid species located across more than one-third of the U.S.

08:07 EST MasterCard reports Q4 gross dollar volume up 8%, purchase volume up 11%

08:06 EST Sesen Bio: Pending Carisma merger in best interests of stockholders - Sesen Bio issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma Therapeutics n response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates or collectively, the "Investor Group." Our attempts to engage with the Investor Group have been driven by our belief that an amicable resolution and successful transaction are in the best interest of our stockholders. Despite the fact that Mr. Radoff built his current position after the merger was announced, and the continued efforts by the Investor Group to disrupt the process to the detriment of our long-term stockholders, we still sought to negotiate with them with the hopes of achieving the best outcome for our stockholders. In contrast, we believe the Investor Group continues to be opportunistic and single-minded, disseminating misleading information about discussions with Sesen Bio and its advisors, and appears willing to sacrifice direct and immediate cash value and the potential upside of ownership in the combined company to secure a short-term payout.

08:04 EST Curaleaf closes operations in California, Colorado and Oregon, cuts payroll 10% - Curaleaf announced the proactive closure of the majority of its operations in California, Colorado and Oregon, beginning this month, as part of its continued effort to streamline its business. Additionally, in an effort to further optimize operations and reduce costs, the company will consolidate cultivation and processing operations in Massachusetts to a single facility in Webster, resulting in the closure of its Amesbury facility. Curaleaf expects to record non-cash restructuring and impairment charges that it will detail on its fourth quarter earnings call in March. Concurrent with these actions, the company has reduced its payroll by 10% which, when coupled with other cost savings initiatives, it expects to realize $60M in gross run-rate expense savings in 2023, exceeding its initial savings target by 50%. The company will exit production and cultivation facilities in California, Colorado and Oregon. While these states have contributed to the growth of Select and other Curaleaf wholesale brands, the company acknowledges the difficult operating environment in these investment states and will instead place a laser focus on cash generation in its core revenue-driving markets moving forward. Curaleaf began aggressive cost-cutting measures in these states in 2022 through facility closures and reductions in workforce. These adjustments were necessary for the future success and profitability of the business and were made as a result of recent legislative decisions, price compression, and lack of enforcement of the illicit market. For context, these markets contributed less than $50M in revenue to Curaleaf last year. Curaleaf expects these market closures will be immediately accretive to its adjusted EBITDA margins and positions it for robust positive free cash flow generation in excess of $125M this year as management executes on its strategic priorities.

07:59 EST Imperial invests $560M in Strathcona to help Canada achieve net zero goals - Imperial said it will further help Canada achieve its net zero goals by investing about $560M to move forward with construction of the largest renewable diesel facility in the country. The project at Imperial's Strathcona refinery near Edmonton is expected to produce more than one billion litres of renewable diesel annually primarily from locally sourced feedstocks and could help reduce greenhouse gas emissions in the Canadian transportation sector by about 3 million metric tons per year, as determined in accordance with Canada's Clean Fuel Regulation. Regulatory approval for the project is expected in the near term. "Imperial supports Canada's vision for a lower-emission future, and we are making strategic investments to reduce greenhouse gas emissions from our own operations and to help customers in vital sectors of the economy reduce their emissions," said Brad Corson, Imperial chairman, president and chief executive officer. "The investment at our Strathcona refinery will deliver immediate benefits to the local economy creating jobs and contributing to a lower-emission energy future for our employees, neighbours and communities."

07:47 EST Nautilus Biotechnology opens office space in San Diego, California - Nautilus Biotechnology announced the opening of its new office space at University Town Center in San Diego, California. The initial 7,000-square-foot space will house Nautilus' San Diego workforce including mechanical engineering, reagent development, software engineering, and bioinformatics, with the ability to expand further as it grows. The expansion of Nautilus' footprint into one of the largest biotechnology and pharmaceutical hubs in the country capitalizes on the company's growing scientific and business momentum. The state-of-the-art facilities feature laboratory and office space that increases Nautilus' capacity for research and development, engineering, software development, and other key functions that will enable the company to further develop its single-molecule proteomics platform.

07:37 EST Accuray's CyberKnife platform selected by European radiosurgery center - Accuray announced that the European Radiosurgery Center Munich has selected a second CyberKnife System, the latest generation CyberKnife S7 System, to enable their team to treat patients. The Center was an early adopter of CyberKnife radiosurgery. Patients eligible for radiosurgery treatments benefit from the shorter overall course of care, typically 1 to 2 sessions in Munich, compared to conventional radiation therapy which often requires 30-40 sessions.

07:36 EST OpGen's Ares Genetics announces granting of key patent in China - OpGen and OpGen subsidiary, Ares Genetics, announced the granting of a key patent by the China National Intellectual Property Administration, CNIPA. The patent with the number ZL 201680044780.7 is titled "Genetic resistance prediction against antimicrobial drugs in microorganism using structural changes in the genome" and describes the invention of a computer implemented method for the identification of genetic variations associated with antibiotic resistance in bacteria. The claims of the granted patent cover the use of bioinformatics to determine in a first step genomic differences between bacteria susceptible to antibiotic therapy and strains that are antibiotic resistant, and to identify in a second step those variants associated with AMR using statistical correlation methods. "The inappropriate and ineffective use of antibiotics is both a widespread problem in patient care and a leading driver of the silent AMR pandemic," says Dr. Arne Materna, CEO of Ares. "We believe there is an urgent need for new diagnostics to detect AMR outbreaks, particularly for healthcare associated infections, and to identify individually effective antibiotic regimen in order to reduce transmissions, improve patient care, and ultimately curb the spread of AMR. We are pleased that claims of the granted patent cover the identification and diagnostic use of genomic variants associated with AMR, and we welcome the decision by the Chinese patent office as we believe it underscores the strategic value of our IP portfolio."

07:33 EST S&T Bancorp raises quarterly dividend to 32c from 29c per share - The dividend is payable February 23 to shareholders of record on February 10.

07:31 EST American National Bankshares announce up to $10M share repurchase authorization - American National Bankshares announced that its Board of Directors has authorized the repurchase of up to $10M worth of the Company's common stock through December 31, 2023. Shares of common stock may be purchased through open market purchases or in privately negotiated transactions at prevailing market prices. The actual means and timing of any purchases, target number of shares and range of prices under the program will be determined by the Company in its discretion and will depend on a number of factors, including the market price of the Company's common stock, general market and economic conditions, share issuances under equity plans, and applicable legal and regulatory requirements.

07:27 EST Benson Hill enters soy collaboration with BioMar - Benson Hill and Denmark-based BioMar announced a strategic collaboration to leverage Benson Hill soy and further assess its sustainability impact on high-performance aquafeed formulations. The companies said, "BioMar is sourcing consecutive seasons of Benson Hill ingredients as part of its commitment to build restorative soy supply chains. Feed holds the primary cost in the farming of aquaculture and is the major contributor to its carbon footprint. Benson Hill advances sustainability goals throughout the ingredient development process - from monitoring regenerative and deforestation-free practices on the farm to producing ingredients that reduce water and energy-intensive protein concentrating steps in processing. Together the companies are assessing how the advantages of Benson Hill ingredients advance BioMar's sustainability program and reduce the impact of aquaculture farming for BioMar customers."

07:26 EST Orthofix announces full commercial launch of of Mariner Deformity System - Orthofix Medical announced the full commercial launch of, and first patient cases involving, the Mariner Deformity Pedicle Screw System.The first product launched since the merger of Orthofix and SeaSpine earlier this month, the Mariner Deformity Pedicle Screw System developed by SeaSpine is built upon the strength and versatility of the foundational Mariner Pedicle Screw System to address the unique clinical requirements of complex adult deformity spine cases. The full commercial launch adds advanced reduction and correction instrumentation, specialized implant technologies, and robust osteotomy tools to deliver efficient and powerful surgical intervention. "The Mariner Deformity System represents an innovative collaboration between surgical minds and a cutting-edge product development team," stated Dennis Cirino, SeaSpine's Senior Vice President, Global Spinal Systems. "Combined with our market-leading biologics and 7D FLASH navigation with machine vision accuracy and segmental registration, this system is designed to deliver a full solution that meets clinical needs and advances the modular platform of the Mariner family."

07:23 EST Greenwave Technology establishes relationships with steel mills - Greenwave Technology has established relationships with leading international and domestic steel mills to secure the best possible prices for each type of metal it processes. During the year ended December 31, 2021, Greenwave received 83% of its revenues from one customer. As a result of the efforts described above, the Company's main customer accounted for 48% of its revenue during the three months ended September 30, 2022. Further, at the Company's Chesapeake facility, Greenwave has been optimizing its processes and procedures for loading containers for shipments both international and domestic. Over the past several months, Greenwave has invested significant resources into its infrastructure and systems to improve its margins, including: Installing a second automotive shredder at its Carrollton facility which is expected come online during Q1 2023 and double the Company's processing capacity while significantly expanding the margins Greenwave realizes on its ferrous products; Utilizing technology to purchase cars directly from customers rather than brokers and auctions; Expanding its fleet of trucks to efficiently transport the significant volume of metal Greenwave processes; Installing a downstream processing system at its Kelford facility which is expected to come online during Q1 2023 to process the auto residue produced by its shredder; and Upgrading the power infrastructure at the Company's Portsmouth facility to enable heavier machinery to process and upgrade its non-ferrous products. Further, Greenwave is pleased to announce that an institutional investor has converted the entirety of its shares of Series Z Preferred Stock. Mr. Danny Meeks, Chairman and CEO of Greenwave, is the sole holder of the remaining shares of Series Z Preferred Stock, the only class of preferred stock outstanding. All of the price protection provisions in Greenwave's equity instruments expired upon the Company's uplisting to Nasdaq on July 22, 2022.

07:22 EST Longevity Biomedical to become public through Denali Capital Acquisition pact - Longevity Biomedical and Denali Capital Acquisition (DECA) announced that they have entered into a definitive business combination agreement. Upon closing of the transaction pursuant to the BCA, the combined company will operate as Longevity Biomedical, Inc. and is expected to list on Nasdaq under the ticker symbol (LBIO). Despite the rapid pace of global population aging, Longevity Biomedical believes the current market for longevity-related products and services is fragmented and that, particularly as it relates to low- and middle-income countries, it is difficult for healthcare consumers to find and purchase the products, technologies and services to address their individual aging needs. To address this unmet need, Longevity Biomedical aims to become a consolidator and leading provider of advanced therapeutic, health monitoring and digital health technologies designed to restore tissue form and function and increase health span for the rapidly growing aging population. To achieve this goal, Longevity intends to build on its existing platform of diversified, late-stage technologies by leveraging its seasoned executive team to continue acquiring first-in-class technologies, products and services that address the growing market of age-related diseases and conditions. Longevity has established an existing pipeline of late-stage, diversified therapeutic candidates addressing cardiovascular disease, ophthalmology and soft tissue reconstruction and repair through the proposed acquisitions of the following technologies. In addition to LB-001, LBI-002, and LBI-101 these clinical stage technologies, Longevity will have, upon the closing of the transactions contemplated by the C&E Agreements described below, a pipeline of preclinical stage indications across its initial therapeutic areas of focus. Longevity also plans to seek to acquire additional cutting-edge health technologies in the areas of health monitoring and digital health solutions. The transaction represents a pro forma equity valuation of approximately $236.2M of the combined company, assuming no redemptions of Denali public shares by Denali's public shareholders. The estimated cash proceeds available to the combined company from the transaction consists of Denali's $85.4M of cash held in trust. The proceeds will be used to complete a Phase 3 study for LBI-201, complete a Phase 2 study for LBI-001, complete a Phase 2 and initiate a Phase 3 study for LBI-101, and complete the formulation and pre-clinical studies for LBI-002. The combined company may seek a $30M pre-transaction PIPE that is expected to close concurrently with the closing of the transaction. Longevity has entered into contribution and exchange agreements with each of Cerevast Medical, a Delaware corporation, Aegeria Soft Tissue, a Delaware limited liability company, and Novokera, a Nevada limited liability company, pursuant to which, immediately prior to the closing of the proposed transaction between Longevity and Denali under the BCA, Longevity will acquire all of the issued and outstanding equity securities of each of the targets from the current equity holders in exchange for shares of common stock of Longevity. The targets are developing the therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair as described above. As a result of the transactions contemplated by the C&E agreements, each of the targets will be a wholly-owned, indirect subsidiary of the combined company upon closing of the transactions contemplated by the BCA. Upon closing of the transactions contemplated under the BCA, and assuming none of Denali's public shareholders elect to redeem their shares of common stock and no additional shares of common stock are issued, it is anticipated that Denali's public shareholders would retain an ownership interest of approximately 34.9% of the combined company, the sponsors, officers, directors and other holders of Denali founder shares and private shares will retain an ownership interest of approximately 10.9% of the combined company, and the Longevity stockholders will own approximately 54.2% of the combined company. The existing stockholder of Longevity and the former target equity holders who receive shares of Longevity common stock at the closing of the target acquisitions are expected to roll 100% of their equity into the combined company. The board of directors of each of Denali and Longevity unanimously approved the transaction, which is expected to occur in Q2 2023. The transaction will require the approval of the shareholders of Denali and Longevity, and is subject to other customary closing conditions including the receipt of certain SEC regulatory approvals.

07:19 EST TG Therapeutics announces commercial launch of BRIUMVI - TG Therapeutics announced the commercial launch of BRIUMVI, for the treatment of relapsing forms of multiple sclerosis, RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with RMS that can be administered in a one-hour infusion following the starting dose. Michael Weiss, the Company's Chairman and Chief Executive Officer, stated, "Our team has been working hard to make BRIUMVI available as quickly as possible, and we are pleased to announce that BRIUMVI is now available to healthcare providers and patients." Mr. Weiss continued, "We continue to be highly focused on ensuring patients who can benefit from BRIUMVI can easily access treatment. We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey. We encourage those interested to visit www.briumivi.com to learn more and also find the full prescribing information."

07:18 EST BioCryst begins enrollment in APeX-P trial evaluating ORLADEYO - BioCryst Pharmaceuticals announced the enrollment of the first patient in the pivotal APeX-P trial evaluating oral, once-daily ORLADEYO in pediatric hereditary angioedema, HAE, patients who are 2 to less than 12 years of age. "Today's announcement marks a very important step in our continuing efforts to reduce the burden of therapy for people living with HAE around the world with oral, once-daily ORLADEYO. Pediatric patients are a particularly important group where the challenges posed by disease and treatment can be significant to these children and their families, especially given the uncertainty they face as they are newly diagnosed during childhood. It is imperative that we strive to help normalize patients' lives, as early experiences can have a lasting impact on how HAE is perceived - and managed - for their entire lifetimes. We are excited by the opportunity to introduce this new pediatric formulation of ORLADEYO that could significantly reduce the treatment burden for children and families impacted by HAE," said Dr. Ryan Arnold, chief medical officer of BioCryst. Following the completion of APeX-P, BioCryst plans to submit a supplemental New Drug Application for the potential expanded use of ORLADEYO for prophylaxis to prevent attacks in pediatric HAE patients.

07:17 EST View's Smart Windows selected by Arden for mixed-use residential development - Arden Group announced that its new mixed-use building will feature smart windows from View. The 20-story building is under development at 4650 Broadway in the Inwood section of Manhattan. The new property, which spans 351,000 square feet, will include 222 residential units upon completion, in addition to 120,000 square feet of commercial and community spaces. View Smart Windows are being installed throughout the building as a premium amenity for its tenants. "Forward-thinking developers like Arden are recognizing that View's smart building technology attract residential tenants and transform the occupant experience," added Dr. Rao Mulpuri, CEO of View. "Our expansion into the multifamily sector continues to grow, particularly in a post-pandemic market, where amenities that promote tenant wellness are more important than ever. This new project with Arden also indicates that the Investment Tax Credit is driving the adoption of smart windows."

07:15 EST Streamline Health, partner signs new contract to utilize RevID in California - Streamline Health Solutions announced it has signed a contract with a partner for the use of RevID at a 350-bed medical center based in California. Through its automated charge reconciliation, RevID will contribute to improved revenue integrity and financial performance. "Our partners are entrusted with helping their clients improve operational and financial results, and we appreciate their faith in RevID's ability to optimize charge capture at this medical center," said Ben Stilwill, President, Streamline Health. "We look forward to accelerating the adoption of our unique, innovative solutions through our partners to help our nation's healthcare providers receive accurate payment for the services they offer."

07:13 EST Archer Daniels increases quarterly dividend 12.5% to 45c per share - ADM's board of directors has declared a cash dividend of 45c per share on the company's common stock. The dividend is payable on March 2, to shareholders of record on February 9.

07:11 EST T. Rowe Price reports year-end AUM $1.27T - Net client outflows of $17.1B for Q4 2022 and $61.7B for 2022.

07:09 EST Cognizant, CoreLogic announce new 10-year services agreement worth $1B - Cognizant announced a new, 10-year services agreement valued at approximately $1B with CoreLogic, a global property information, analytics and data-enabled solutions provider. Building on their highly successful, decade-long strategic relationship, CoreLogic and Cognizant have agreed to expand their existing alliance. This new agreement features: Expansion of Cognizant's services and anticipated value for CoreLogic, leveraging Cognizant's digital transformation expertise particularly in cloud migration, automation, and industry-specific platform innovations; Significant commitment to innovation and automation expected to benefit CoreLogic through lower technology and operations costs over the lifetime of the agreement; and, Strong focus on driving customer experience improvement through operational excellence.

07:06 EST Comcast increases annualized dividend to $1.16 per share - Comcast announced that it increased its dividend by 8c to $1.16 per share on an annualized basis, up 7.4% year-over-year. In accordance with the increase, the board of directors declared a quarterly cash dividend of $0.29 a share on the company's common stock, payable on April 26, to shareholders of record as of the close of business on April 5.

07:05 EST American Airlines reports operating margin of 10.5% for Q4 - The company said, "American produced revenues of $13.2 billion in the fourth quarter, an increase of 16.6% versus the same period in 2019 and the highest fourth-quarter revenue in company history, driven by the continued strength of the demand environment. This record revenue was achieved while flying 6.1% less capacity than the same period in 2019. On both a GAAP basis and excluding the impact of net special items, the company produced an operating margin of 10.5% in the quarter. American also produced record revenues of $49 billion for the full year, resulting in full-year profitability.:

07:03 EST Denali Capital Acquisition, Longevity Biomedical announce combination pact - Longevity Biomedical and Denali Capital Acquisition Corp. announced that they have entered into a definitive business combination agreement. Upon closing of the transaction pursuant to the BCA, the combined company will operate as Longevity Biomedical, Inc. and is expected to list on Nasdaq under the ticker symbol "LBIO." The transaction represents a pro forma equity valuation of approximately $236.2M of the Combined Company, assuming no redemptions of Denali public shares by Denali's public shareholders. The estimated cash proceeds available to the Combined Company from the transaction consists of Denali's $85.4M of cash held in trust. The proceeds will be used to complete a Phase 3 study for LBI-201, complete a Phase 2 study for LBI-001, complete a Phase 2 and initiate a Phase 3 study for LBI-101, and complete the formulation and pre-clinical studies for LBI-002. The Combined Company may seek a $30M pre-transaction PIPE that is expected to close concurrently with the closing of the transaction. Upon closing of the transactions contemplated under the BCA, and assuming none of Denali's public shareholders elect to redeem their shares of common stock and no additional shares of common stock are issued, it is anticipated that Denali's public shareholders would retain an ownership interest of approximately 34.9% of the Combined Company, the sponsors, officers, directors and other holders of Denali founder shares and private shares will retain an ownership interest of approximately 10.9% of the Combined Company, and the Longevity stockholders will own approximately 54.2% of the Combined Company. The existing stockholder of Longevity and the former Target equity holders who receive shares of Longevity common stock at the closing of the Target acquisitions are expected to roll 100% of their equity into the Combined Company. The board of directors of each of Denali and Longevity unanimously approved the transaction, which is expected to occur in Q2 2023. The transaction will require the approval of the shareholders of Denali and Longevity, and is subject to other customary closing conditions including the receipt of certain SEC regulatory approvals.

06:53 EST Southwest sees FY23 economic fuel costs per gallon $2.90-$3.00 - Sees FY23 ASMs up 16%-17%. Sees FY23 CASM-X down 6%-8%. Sees FY23 effective tax rate 23%-24%. Sees FY23 capital spending $4B-$4.5B.

06:47 EST Northrop Grumman provides 2023 sector guidance - For 2023 sees: Aeronautics Systems sales mid $10B, OM rate ~ 10%; Defense Systems sales mid $5B, OM rate ~12%; Missions Systems sales high $10B, OM rate low 15%; Space Systems sales mid $13B, OM rate mid 9%; Eliminations low ($2B), OM rate mid 13%.

06:33 EST Roche launches COVID-19 PCR test to detect XBB.1.5 Omicron sub-variant - Roche and its subsidiary TIB Molbiol announced they have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. "The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment strategies. The test, VirSNiP SARS-CoV-2 Spike F486P, is for use on the LightCycler 480 II and cobas z 480," the company said. "Roche continues to develop timely diagnostic innovations related to COVID-19 by providing valuable insights - helping scientists and physicians understand this new strain, how it differs from other variants, and the impact it may have on public health," said Matt Sause, CEO of Roche Diagnostics. "Since the start of this global health crisis, Roche has been committed to bringing effective diagnostic solutions to address unmet needs to healthcare communities worldwide."

06:14 EST Dow Inc. outlines target actions to deliver $1B in cost savings in FY23 - Dow Inc. outlined a series of targeted actions aligned to its previously stated plan to achieve $1B in cost savings in 2023. The actions will aim to optimize the company's cost structure in response to near-term macroeconomic uncertainty, while maintaining its long-term competitiveness across the economic cycle. Specifically, Dow expects to realize $1B in cost savings in 2023 through: structural improvements of $500 million, maintaining a low cost-to-serve operating model; optimizing labor and services costs, including a global workforce reduction of approximately 2,000 roles; shutting down select assets, while further evaluating Dow's global asset base, particularly in Europe, to ensure long-term competitiveness and enhance cost efficiency and increasing productivity via end-to-end process improvements. Operating expense reductions of $500M, focused on near-term cash flow include: decreasing turnaround spending, with a continued focus on maintaining safety and reliability; reducing purchased raw materials, logistics and utilities costs and aligning spending levels to the macroeconomic environment. "We are taking these actions to further optimize our cost structure and prioritize business operations toward our most competitive, cost-advantaged and growth-oriented markets, while also navigating macro uncertainties and challenging energy markets, particularly in Europe," said Jim Fitterling, Dow chairman and CEO. "We remain committed to capitalizing on our long-term growth opportunities in a disciplined and balanced manner, and these actions further position us to advance our Decarbonize and Grow strategy and strengthen our competitive position." The company will record a charge of $550M to $725M in the first quarter of 2023 for costs associated with these activities, which primarily include severance and related benefit costs; costs associated with exit and disposal activities; and asset write-downs and write-offs. Longer-term, Dow remains on track to grow its underlying EBITDA by greater than $3B by 2030 while reducing its carbon emissions by 30% versus its 2005 baseline as it progresses on its path to carbon neutrality by 2050.

06:08 EST Tractor Supply reports Q4 SSS up 8.6%

06:06 EST Dow Inc. sees initial positive signs from moderating inflation in U.S. - "As we enter 2023, we remain focused on managing near-term dynamics while continuing to position the company for long-term value creation," said Fitterling. "While we see initial positive signs from moderating inflation in the U.S., improving outlook for energy in Europe, and re-opening in China, we continue to be prudent and proactive by implementing a playbook of targeted actions focused on optimizing labor and purchased service costs, reducing turnaround spending, and enhancing productivity. These actions are collectively expected to deliver $1 billion in cost savings. Going forward, we will continue to maintain our disciplined and balanced approach to capital allocation and focus on cash flow generation, while executing our strategic priorities for long-term sustainable and profitable growth."

06:02 EST Tractor Supply sees FY23 comparable store sales growth of 3.5%-5.5%

05:56 EST Murphy Oil increases quarterly dividend 10% to 27.5c per share - The board of directors of Murphy Oil declared a quarterly cash dividend on the common stock of Murphy Oil Corporation of 27.5c per share, or $1.10 per share on an annualized basis. This represents a 120% increase since fourth quarter 2021 and a 10% increase from the previous quarter. The dividend is payable on March 1 to stockholders of record as of February 13.

05:21 EST SAP sees FY23 free cash flow EUR 5B - Sees FY23 effective tax rate 28%-32%. Sees FY23 cloud revenue EUR 15.3B-EUR 15.7B. Sees FY23 cloud and software revenue EUR 28.2B-EUR 28.7B.